Associated Genetic Biomarkers
TOP2A Amplification is present in 0.55% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, adenocarcinoma of the gastroesophageal junction, and cutaneous melanoma having the greatest prevalence .
TOP2A Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains TOP2A Amplification as an inclusion criterion, 1 is phase 2 (1 open).
Trials with TOP2A Amplification in the inclusion eligibility criteria most commonly target breast carcinoma .
Capecitabine and targeted therapy agent are the most frequent therapies in trials with TOP2A Amplification as an inclusion criteria .
Significance of TOP2A Amplification in Diseases
Breast Carcinoma +
TOP2A is altered in 0.21% of breast carcinoma patients with TOP2A Amplification present in 0.03% of all breast carcinoma patients .
TOP2A Amplification is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TOP2A Amplification and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.